A Phase I/II, open label, dose-escalation clinical trial of TLC178 in paediatric rhabdomyosarcoma patients
Phase of Trial: Phase I/II
Latest Information Update: 09 Jul 2018
Price : $35 *
At a glance
- Drugs Vinorelbine (Primary) ; Cyclophosphamide
- Indications Rhabdomyosarcoma; Sarcoma
- Focus Adverse reactions; Therapeutic Use
- 09 Jul 2018 According to a Taiwan Liposome Company media release, Clearance received from the U.S. Food and Drug Administration (FDA) for the TLC178 Investigational New Drug (IND) applications, allowing Phase I/II trials to proceed in the US.
- 07 Jun 2018 New trial record
- 03 Jun 2018 According to a Taiwan Liposome Company media release, today announced the submission of an Investigational New Drug (IND) application with the U. S. Food and Drug Administration (FDA).